Vinorelbine (Navelbiner`): A Third-Generation Vinca Alkaloid

References

• Noble R L, Beer C T, Cutis J H. Further biological activities of vincaleukoblastine—An alkaloid isolated from Vinca rosea (L). Biochem Pharmacol 1858; 1: 347–348
   Google Scholar
• Frei E, Franzino A, Schneider B L, et al. Clinical studies of vinblastine. Cancer Chemother Rep 1961; 12: 125–129
   PubMedGoogle Scholar
• Budman D R. New vinca alkaloids and related compounds. Semin Oncol 1992; 19: 639–645
   PubMed Web of Science ®Google Scholar
• Maugeney P, Andriamialisoa R, Lallemand J Y, et al. 5′Noranhy-drovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 1979; 35: 2175–2179
   Web of Science ®Google Scholar
• Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 1989; 16(Suppl 4)9–14
   PubMedGoogle Scholar
• Binet S, Fellous A, Lataste H, et al. In situ analysis of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989; 16(Suppl 4)5–8
   PubMedGoogle Scholar
• Etievant C, Pauwels O, Kiss R. Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines. J Cancer Res Clin Oncol 1993; 120: 76
   PubMed Web of Science ®Google Scholar
• Zhou X J, Placidi M, Rahmani R. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 1994; 14: 1017–1022
   PubMed Web of Science ®Google Scholar
• Wargin W A, Sol Lucas V. The clinical pharmacokinetics of vi-norelbine (Navelbine). Semin Oncol 1994; 21(Suppl 10)21–27
   PubMedGoogle Scholar
• Zhou-Pan X R, Seree E, Zhou X J, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 1993; 53: 5121–5126
   PubMed Web of Science ®Google Scholar
• Tobe S W, Siu L L, Jamal S A, et al. Vinblastine and erythromycin: An unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995; 35: 188–190
   PubMed Web of Science ®Google Scholar
• Rajaonarison J F, Lacarelle B, Catalin J, et al. Effect of anticancer drugs on the glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes. Drug Metal. Dispos 1993; 21: 823–829
   PubMed Web of Science ®Google Scholar
• Knick V C, Miller C G. In vivo derivation of a murine P 388 leukemia subline resistant to 5′nor-anhydrovinblastine(Navelbine) and its cross-resistance profile. Proc Am Assoc Cancer Res 1992; 33: 462
   Google Scholar
• Mazzoni A, Trave F, Russo P, et al. Generation and characterization of a low-degree drug resistant human tumor cell line. Oncology 1990; 47: 488–494
   PubMed Web of Science ®Google Scholar
• Debal V, Allam N, Morjani H, et al. Characterization of a Navel-bine-resistant bladder carcinoma ceil line cross-resistant to taxoids. Br J Cancer 1994; 70: 1118–1125
   PubMed Web of Science ®Google Scholar
• Photiou A, Sheikh M N, Bafaloukos D, et al. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol 1992; 118: 249–254
   PubMed Web of Science ®Google Scholar
• Burris H A, III, Fields S. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 1994; 5(Suppl 10)14–20
   Google Scholar
• Ashizawa T, Miyoshi K, Asada M, et al. Antitumor activity of Navelbine (vinrorelbine ditartrate), a new vinca alkaloid analog. Gan to Kagaku Ryoho 1993; 20: 59–66
   PubMedGoogle Scholar
• Ashizawa T, Asada M, Kobayashi E, et al. Combination effect of Navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice. Anti-cancer Drugs 1993; 4: 577–583
   PubMed Web of Science ®Google Scholar
• Bissery M C, Vrignaud P, Bayssas M, et al. Preclinical in vivo activity of docetaxel containing combinations. Proc Am See Clin Oncol 1995; 14: 489
   Google Scholar
• Adams D J. Synergy of Navelbine-taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res 1994; 35: 327
   Google Scholar
• Knick V C, Eberwein D J, Miller C G. Preclinical activity of Navelbine and taxol drug combinations. Proc Am Assoc Cancer Res 1994; 35: 327
   Google Scholar
• Dine T, Luyckx M, Cazin J C, et al. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharmaceut 1991; 77: 279–285
   Web of Science ®Google Scholar
• American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990; 47: 1033–1049
   PubMedGoogle Scholar
• Harrison B R. Safe handling of cytotoxic drugs: a review. The Chemotherapy Source Book, M C Perry. Williams & Wilkins, Baltimore 1992; 799–832
   Google Scholar
• Trissel L A, Martinez J F. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tratrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994; 51: 495–497
   PubMedGoogle Scholar
• Investigator's Brochure. Burroughs-Wellcome Company, on file with the U.S. Federal Food and Drug Administration
   Google Scholar
• Krikorian A, Breiilout F. Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie 1991; 14: 7–12
   PubMed Web of Science ®Google Scholar
• Rahmani R, Gueritte F, Martin M, et al. Comparative pharmacokinetics of antitumor vinca alkaloids: Intravenous bolus injections of Navelbine and related alkaloids to cancer patients and rats. Cancer Chemother Pharmacol 1986; 16: 223–228
   PubMed Web of Science ®Google Scholar
• Leveque D, Merle-Melet M, Bresler L, et al. Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemother Pharmacol 1993; 32: 487–490
   PubMed Web of Science ®Google Scholar
• Marquet P, Lachatre G, Debord J, et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992; 42: 545–547
   PubMed Web of Science ®Google Scholar
• Rahmani R, Bruno R, Iliadis A, et al. Clinical pharmacokinetics of the antitumor drug Navelbine (5′-noranhydrovinblastine). Cancer Res 1987; 47: 5796–5799
   PubMed Web of Science ®Google Scholar
• Jehl F, Quoix E, Leseque D, et al. Pharmacokinetic and preliminary metabolic fate of Navelbine in humans as determined by high performance liquid chromatography. Cancer Res 1991; 51: 2073–2076
   PubMed Web of Science ®Google Scholar
• Rahmani R, Zhou X J, Bore P, et al. Oral administration of 3H-Nav-elbine in patients: Comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anti-cancer Drugs 1991; 2: 405–410
   PubMed Web of Science ®Google Scholar
• Zhou X J, Bore P, Monjanel S, et al. Pharmacokinetics of Navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol 1992; 29: 66–70
   Web of Science ®Google Scholar
• Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59: 32–40
   PubMed Web of Science ®Google Scholar
• Madden T, Bleyer A, Hohneker J, et al. The pharmacokinetics of vinorelbine (Navelbine, NVB) in pediatric cancer patients. Proc Am Soc Clin Oncol 1995; 14: 168
   Google Scholar
• Rowinsky E K, Noe D A, Trump D L, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine inpatients with solid tumors. J Clin Oncol 1994; 12: 1754–1763
   PubMed Web of Science ®Google Scholar
• Leveque D, Jehl F, Quoix E, et al. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 1992; 32: 1096–1098
   PubMed Web of Science ®Google Scholar
• Pinedo H M. Vinorelbine: A horse of a different color. J Clin Oncol 1994; 12: 1745–1746
   PubMed Web of Science ®Google Scholar
• Mathe G, Reizenstein P. Phase I pharmacologic study of a new vinca-alkaloid: Navelbine. Cancer Leu 1985; 27: 285–293
   PubMed Web of Science ®Google Scholar
• Hohneker J. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21(Suppl 10)42–47
   PubMedGoogle Scholar
• Le Chevalie T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360–367
   PubMed Web of Science ®Google Scholar
• Khayal D, Covelli A, Variol P, et al. Phase I and pharmacologic study of intravenous (i.v.) vinorelbine (VRL) in patients (PTS) with solid tumors. Proc Am Soc Clin Oncol 1995; 14: 469
   Google Scholar
• Brosio C, Cinat G, Mickiewicz E, et al. Granulocytic colony stimulating factors (GCSF) support in weekly chemotherapy (CT) with vinorelbine (NVB). Proc Am Soc Clin Oncol 1993; 12: 144
   Google Scholar
• Cinat A, Brosio C, Mickiewica E, et al. Filgrastim (G-CSF) support ill weekly chemotherapy with vinorelbine (VNB). Proc Am Soc Clin Oncol 1995; 14: 261
   Google Scholar
• Crawford J, O'Rourke M A, Herndon J, et al. Sequential trials of vinorelbine (Navelbine, NVB) with carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am Soc Clin Oncol 1995; 14: 376
   Google Scholar
• Toussaint C, Izzo J, Spielmann M, et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 1994; 12: 2102–2112
   PubMed Web of Science ®Google Scholar
• Bowen K, Burris H, Rodriguez G, et al. A phase I trial of chronic oral Navelbine administration. Proc Am Assoc Cancer Res 1992; 35: 519
   Google Scholar
• Budman D R, Schuiman P, Marks M, et al. Phase I Vinzolidine. Cancer Treat Rep 1983; 68: 979–982
   Google Scholar
• Cecchi R, Tuci F, Giomi A, et al. Supravenous hyperpigmentation induced by vinorelbine. Dermatology 1994; 188: 244
   PubMed Web of Science ®Google Scholar
• Lozano M, Muro H, Triguboff E, et al. A randomized trial for effective prevention of navelbine (NVB) related phlebitis. Proc Am Soc Clin Oncol 1995; 14: 535
   Google Scholar
• Cvitkovic E, Izzo J. The current and future place of vinorelbine in cancer therapy. Drugs 1992; 44(Suppl 4)36–45
   PubMedGoogle Scholar
• Yokoyama A, Furuse K, Niitani H, et al. Multi-institutional phase II study of Navelbine (vinorelbine) in non-small cell lung cancer. Proc Am Soc Clin Oncol 1992; 11: 287
   Google Scholar
• Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991; 14: 115–119
   PubMed Web of Science ®Google Scholar
• Kusunoki Y, Furuse K, Yamori S, et al. Randomized phase II study of vinorelbine (VRB) vs. vindesine (VDS) in previously untreated non-small cell lung cancer (NSCLC): Final results. Proc Am Soc Clin Oncol 1995; 14: 353
   Google Scholar
• Berthaud P, Le Chevalir T, Ruffle P, et al. Phase I-II study of vinorelbine (Nacelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992; 28: 1863–1865
   Google Scholar
• Balbiani L, Coppola F, Blajman C, et al. Navelbine (NVB) vs NVB plus cisplatin (P) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993; 12: 352
   Google Scholar
• Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus venorel-bine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Ann Oncol 1994; 5: 37–42
   PubMed Web of Science ®Google Scholar
• Lorusso V, Pezzella G, Catino A M, et al. Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alone. Int J Oncol 1995; 6: 65–68
   PubMed Web of Science ®Google Scholar
• Jacoulet P, Dubiez A, Depoerre A, et al. One-week versus 3-weeks intervals in the administration of cisplatine in combination with vinorelbine: A randomized study in non-small-cell cancer (NSCLC). Proc Am Soc Clin Oncol 1992; 11: 301
   Google Scholar
• Perol M, Guerin J C, Kleisbauer J P, et al. Multicenter randomized trial comparing cisplatin-mitomycin-vindesine vs cisplatin-mi-tomycin-Navelbine in advanced non small cell lung cancer (NSCLC). J Int Assoc Study Lung Cancer 1994; 11: 114
   Google Scholar
• O'Rourke M, Crawford J, Schiller J, et al. Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine in a randomized controlled trial. Proc Am Soc Clin Oncol 1993; 12: 343
   Google Scholar
• Sanlomaggio C, Righi R, Tucci E, et al. Carboplatin (C) and vinorelbine (V) in metastatic (M) nonsmall cell lung cancer (NSCLC). Preliminary results, J Int Assoc Study Lung Cancer 11(Suppl 1994; 1): 125
   Google Scholar
• Crawford J, O'Rourke M A. Vinorelbine (Navelbine)/carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor. Semin Oncol 1994; 21(Suppl 10)73–78
   PubMedGoogle Scholar
• Cornelia P, Casaretti R, Daponte A, et al. Combination of vinorelbine, cisplatin, and etoposide in advanced non-small cell lung carcinoma: A pilot study. J Chemother 1994; 6: 67–71
   Web of Science ®Google Scholar
• Jacoulet P, Depierre A, Gamier G, . Study of combined Navelbine-cisplatin-VP-16 in the treatment of non small cell lung cancer. Navelbine (Vinorelbine): Update and New Trends, P Solal-Celigny, et al. John Libby Eurotex, Paris 1991; 171–177
   Google Scholar
• Carles P, Quoix E, Guerin J-C, . Presentation of Navelbine combinations in the treatment of non small cell lung cancer. Navelbine (Vinorelbine): Update and New Trends, P Solal-Celigny, et al. John Libbey Eurotex, Paris 1991; 137–140
   Google Scholar
• Gridelli C, De Placido S, Pepe R, et al. Phase I study of epirubicin (edx) plus vinorelbine (vnr) with or without G-CSF in advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993; 12: 342
   Google Scholar
• Gridelli C, Rosi A., Plazzolo G, et al. Mitomycin C, etoposide and vinorelbine (MEV II) in the treatment of metastatic stage IV non small cell lung cancer. Tumori 1994; 80: 128–130
   PubMed Web of Science ®Google Scholar
• Cornelia P, Frasci G, De Cataldis G, et al. Vinorelbine (VNR) combined to cisplatin/carboplatin (CBDCA) and atoposide (VP-16) in advanced NSCLC. Preliminary analysis of a three arm phase III randomized trial. Proc Am Soc Clin Oncol 1995; 14: 384
   Google Scholar
• Souquet P J, Fournel P, Lombard-Bohas C H, et al. Cisplatin (CDDP), ifospfamide (IFM) with various dosages of vinorelbine (NVB) in non-resectable non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 367
   Google Scholar
• Poudenx M, Otto J, Ferrero J M, et al. Vinorelbine (VNR), ifosfamide (IFX), and cisplatin (CDDP) in non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 366
   Google Scholar
• Barone C, Pozzo C, Cassano A, et al. Phase II study of vinorelbine, cisplatin, and ifosfamide combination for advanced non small cell lung canceripreliminary results. Proc Am Soc Clin Oncol 1995; 14: 369
   Google Scholar
• Hoffman P, Drinkard L, Masters G, et al. Ifosfamide plus Navelbine: A phase I study in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 358
   Google Scholar
• Canobbio L, Boccardo F, Pastorino G, et al. Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 1989; 16(Suppl 4)33–36
   PubMed Web of Science ®Google Scholar
• De Cremoux H, Monnet I, Azli N, et al. Fluorouracil (FU)/leuco-vorin (AF)/vinorelbine (VNB)/cisplatin (p) in non small cell lung cancer (NSCLC): A phase II study. Proc Am Soc Clin Oncol 1992; 11: 303
   Google Scholar
• Tredaniel J, Dieras V, Ferme C, . Alternative to cisplatin: 5FU-Navelbine combination. Navelbine (Vinorelbine): Update and New Trends, P Solal-Celigny, et al. John Libbey Eurotex, Paris 1991; 163–169
   Google Scholar
• Masters G, Drinkard L, Hoffman P, et al. A phase I study of concomitant chemoradiotherapy with cisplatin (CDDP) and navelbine (NVB) for advanced malignancies of the chest. Proc Am Soc Clin Oncol 1995; 14: 378
   Google Scholar
• Viallet J, Rosseau P, Souhami L, et al. A phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine (Navelbine) followed by accelerated thoracic irradiation (TRT) in inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 337
   Google Scholar
• Jassem J, Karnicka-Mlodkowska H, Van Pottelsberghe C H, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lungcancerpatients. Eur J Cancer 1993; 29A: 1720–1722
   PubMed Web of Science ®Google Scholar
• Furuse K, Kawahara M, Fukuoka M, et al. Early phase II study of vinorelbine (VNR) in small cell lung cancer. J Int Assoc Study Lung Cancer 1994; 11(Suppl 1)107
   Google Scholar
• Depierre A, Le Chevalier T, Quoix E, et al. Phase II study of navelbine (NVB) in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1995; 14: 348
   Google Scholar
• Tummarello D, Graziano F, Giordani P. A phase II study of vinorelbine (VNB) in small cell lung cancer (SCLC) patients (PTS) unsuitable for standard chemotherapy (CHT). Proc Am Soc Clin Oncol 1995; 14: 369
   Google Scholar
• Budman D R. Investigational agents. The Chemotherapy Sourcebook, M C Perry. Williams & Wilkins., Baltimore 1992; 462
   Google Scholar
• Boccardo F, Canobbio L, Pastorino G, et al. Phase II study of Navelbine (nvb) in advanced breast cancer. Invest New drugs 1989; 7: 426
   Google Scholar
• Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5: 423–426
   PubMed Web of Science ®Google Scholar
• Romero A, Rabinovich M G, Vallejo C T, et al. Vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1994; 12: 336–341
   PubMed Web of Science ®Google Scholar
• Marty M, Extra J M, Dieras V, et al. A review of the antitumor activity of vinorelbine in breast cancer. Drugs 1992; 44(Suppl 4)29–35
   PubMedGoogle Scholar
• Twelves C J, Dobbs N A, Curnow A, et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994; 70: 990–993
   PubMed Web of Science ®Google Scholar
• Bruno S, Puerto V L, Mickiewicz E, et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 1995; 18: 392–396
   PubMed Web of Science ®Google Scholar
• Vogel C, O'Rourke M, Weber B, et al. The safety of IV Navelbine in elderly patients with advanced breast cancer (ABC). Presented at the 5th International Congress on Anti-Cancer Chemotherapy. 1995
   Google Scholar
• Winer E, O'Rourke M, Vogel C, et al. A US multicenter phase II trial of oral Navelbine in elderly women with advanced breast cancer. Breast Cancer Res Treat 1993; 27: 136
   Google Scholar
• Fumoleau P, Delaado F M, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245–1252
   PubMed Web of Science ®Google Scholar
• Livingston R B, Ellis G K, Williams M A. Weekly vinorelbine (Navelbine, NVB) + G-CSF in taxol-refractory metastatic breast cancer (MBC); a phase 1–11 study. Proc Am Soc Clin Oncol 1995; 14: 110
   Google Scholar
• Terzoli E, Nistico C, Ranuzzi M, et al. Weekly vinorelbine (V) plus G-CSF in previously treated patients with advanced breast cancer. Breast Cancer Res Treat 1996; 37(Suppl)236a
   Google Scholar
• Pace A, Terzoli E, Bove L, et al. Vinorelbine neurotoxicity: Clinical and neurophysiological findings. 5th International Congress on Anti-cancer Chemotherapy. 1995; 221
   Google Scholar
• Jones S, Winer E, Vogel C, et al. A multicenter randomized trial of iv Navelbine vs iv alkeran in patients with anthracycline refractory advanced breast cancer. Proc Am Soc Clin Oncol 1994; 13: 103
   Google Scholar
• Ray-Coquard I, Blay J Y, Bachelot T, et al. Continuous infusion of vinorelbine (VNB) and bolus cisplalinum (CDDP) (CIVIC Regimen). An efficient regimen in hormoresistant metastatic breast cancers (MBC) after failure of anthracycline and/or paclitaxel. Proc Am Soc Clin Oncol 1995; 14: 137
   Google Scholar
• Hochster H, Vogel C, Blumenreich M, et al. A multicenter phase II study of Navelbine (NVB) and doxorubicin as first line chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 1994; 13: 100
   Google Scholar
• Spielmaim M, Dorval T, Turpin F, et al. Phase II trial of vinorel-bine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994; 12: 1764–1770
   PubMed Web of Science ®Google Scholar
• Blajman C, Balbiani L, Block J, et al. Navelbine (N) plus adriamy-cin (A) vs FAC in advanced breast cancer. Proc Am Soc Clin Oncol 1993; 12: 92
   Google Scholar
• Chadjaa M, Izzo J, May-Levin F, et al. Preliminary data on 4′epiadriamycine (epi)-vinorelbine (VNB): A new active combination in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1993; 12: 88
   Google Scholar
• Terzoli E, Nistico C, Ranuzzi M, et al. Weekly epirubicin plus vinorelbine in advanced breast cancer: Preliminary results. Proc Am Soc Clin Oncol 1995; 14: 120
   Google Scholar
• Van Praagh I, Martineau N, Cure H, et al. Efficacy of a chemotherapy regimen combining vinorelbine, epirubicine and methotrexate (VEM) in locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol 1993; 12: 95
   Google Scholar
• Meriggi F, Zaniboni A, Arcangeli G, et al. VELF: An active outpatient regimen for aggressive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1994; 13: 91
   Google Scholar
• Dieras V, Pierga J Y, Extra J M, et al. Results of a combination of Navelbine (NVB) and fluorouracil (FU) in advanced breast cancer (ABC) with a group sequential design (GSD). Ann Oncol 3(Suppl 1992; 5): 46
   Google Scholar
• Leone B, Vallejo C, Romero A, et al. Ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy (FLC) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1995; 14: 122
   Google Scholar
• Scheithauer W, Kornek G, Haider K, et al. Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res Treat 1993; 26: 49–53
   PubMed Web of Science ®Google Scholar
• Cole J T, Gralla R J, Kardinal C G. Navelbine and mitomycin C: Combination therapy in advanced breast cancer. 17th Annual San Antonio Breast Cancer Symposium. 1995
   Google Scholar
• Ferrero J M, Wendling J L, Hock M, et al. Mitoxanthrone (mtz)-vi-norelbine (vnr) as first line chemotherapy (ct) in metastatic breast cancer (MBC): A pilot study. Proc Am Soc Clin Oncol 1993; 12: 108
   Google Scholar
• Kayitalire L, Spielmann M, Brain E, et al. Salvage chemotherapy (CT) with combination of mitoxanthrone (MTZ) and vinorelbine (VNR) in resistant to anthracyclines advanced breast cancer. Proc Am Soc Clin Oncol 1993; 12: 90
   Google Scholar
• Colleoni M, Gaion F, Sgarbossa P, et al. Phase II study of mitoxanthrone, fluorouracil plus folates and vinorelbine inpatients with previously treated advanced breast cancer (ABC). 5th International Conference on Anticancer Chemotherapy. 1995; 112
   Google Scholar
• Bolto H G, Galmarini F, Galvez C. Mitoxanthrone (M), ifosfamide (I), vinorelbine (V), (MIV) and GM-CSF in refractory metastatic breast cancer (RMBC). Proc Am Soc Clin Oncol 1994; 13: 85
   Google Scholar
• Terzoli E, Nistico C, Ranuzzi M, et al. Weekly epirubicin (E) plus vinorelbine (V) and G-CSF in advanced breast cancer (ABC): An active treatment. Breast Cancer Res Treat 1996; 37(Suppl)113a
   Google Scholar
• Budman D R, Calabro A, Stiel L, et al. In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: sequence dependent effects causing synergism or antagonism. Proc Am Assoc Cancer Res 1996; 37: 2493a
   Google Scholar
• Chang A Y, Garrow G C. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 1995; 22: 6670
   Google Scholar
• Fazeny B, Zifko U, Meryn S, et al. Navelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel. Proc Am Soc Clin Oncol 1994; 13: 57
   Google Scholar
• Vogel C, Hochster H, Blumenreich M, et al. A US multicenter phase II study of IV Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC). Proc Am See Clin Oncol 1995; 14: 91
   Google Scholar
• Conroy T, Etienne P L, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 1996; 14: 164–170
   PubMed Web of Science ®Google Scholar
• George M J, Heron J F, Kerbrat P, et al. Navelbine in advanced ovarian epithelial cancer: A study of the French oncology centers. Semin Oncol 1989; 16(Suppl 4)30–32
   PubMed Web of Science ®Google Scholar
• Pinon G, Pinel M C, Goudier M J, et al. Study of vinorelbine (V) combined with hexamethylmelamine (H) (Combination V-H) in adenocarcinoma of the ovary: Results of a phase I-IIA trial, NHO-88, of ARTC Ovarian Group. Bull Cancer (Paris) 1991; 78: 1119–1131
   PubMedGoogle Scholar
• Canobbio L, Boccardo F, Guarneri D, et al. Phase II study of Navelbine in advanced renal cancer. Eur J Cancer 1991; 27: 804–805
   PubMed Web of Science ®Google Scholar
• Wilding G, Kirkwood J, Clamon G, et al. Phase II trial of Navelbine in metastatic renal cancer. Proc Am Soc Clin Oncol 1993; 12: 253
   Google Scholar
• Bnchekroun S, Chouffai Z, Harif M, . Clinical study of Navelbine activity in Hodgkin's disease. Phase II study. Navelbine (Vinorelbine): Update and New Trends, P Solal-Celigny, et al. John Libbey Eurotex, Paris 1991; 261–264
   Google Scholar
• Bruno S, Savignano R, Corrado C, et al. Vinorelbine (NVB): A new vinca alkaloid active in refractory/relapsed lymphomas. A phase II study. Proc Am Soc Clin Oncol 1994; 13: 382
   Google Scholar
• Romanini A, Surbone A, Ricci S, et al. Phase II study of continuous infusion of vinorelbine (CIV) in patients with locally pretreated advanced head and neck cancer. Proc Am Assoc Cancer Res 1993; 34: 205
   Google Scholar
• Gebbia V, Testa A, Valenza R, et al. A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 1993; 29A: 1358–1359
   PubMed Web of Science ®Google Scholar
• Gebbia V, Testa A, Valenza R, et al. Vinorelbine plus cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell head and neck carcinoma. Proc Am Soc Clin Oncol 1993; 12: 283
   Google Scholar
• Fields S, Burris H, III, Wilding G, et al. Evaluating the role of Navelbine in hormone-refractory prostate cancer (HRPC): A clinical benefit model. Proc Am Soc Clin Oncol 1994; 13: 235
   Google Scholar
• Kris M G, Gralla R J, Kalman L A, et al. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 1985; 69: 387–395
   PubMedGoogle Scholar
• Carrato A, Rosell R, Artal A, et al. Preliminary results of a phase II trial of biweekly vinorelbine as a single agent in nonsmall cell lung cancer (NSCLC). Spanish Cancer Group. Proc Am Soc Clin Oncol 1994; 13: 338
   Google Scholar
• Crivellari D, Versonesi A, Sacco C, et al. Phase II study of vinorelbine (V) in 50 patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 355
   Google Scholar
• Fernandez O, Bruno S, Mickiewicz E, et al. Randomized prospective comparison of Navelbine (NVB) and cisplatin vs. Navelbine alone in patients with inoperable non small cell lung cancer. J Cancer Res Clin Oncol 116(Suppl 1990; 1): 111
   Google Scholar
• Kusunoki Y, Furuse Y, Yamori S, et al. Randomized phase II study of vinorelbine (VNR) vs. vindesine (VD) in previously untreated non-small cell lung cancer (NSCLC). J Int Assoc Study Lung Cancer 11(Suppl 1994; 1): 113
   Google Scholar
• Lonardi F, Pavanato G, Jirillo A, et al. Vinorelbine (VNB) as single agent chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 338
   Google Scholar
• Masotti A, Zannini G, Poggi R, et al. Vinorelbine monochemotherapy in non-small cell lung cancer: Experience in patients with low performance status. Monaldi Arch Chest Dis 1994; 49: 197–200
   PubMedGoogle Scholar
• Sanloro A, Maiorino L, Santoro M. Second-line therapy with vinorelbine in the weekly monotherapy for the treatment of advanced non small cell lung cancer. J Int Assoc Study Lung Cancer 11(Suppl 1994; 1a): 113
   Google Scholar
• Vokes E E, Rosenberg R, Jahnazeb M, et al. Multicenter study of oral Navelbine (NVB) in previously untreated stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993; 12: 336
   Google Scholar
• Adenis A, Vanlemmens L, Foumier C H, et al. Mitoxanthrone (DHAD) and vinorelbine (VNR) as a primary treatment of locoregional breast cancer (BC). Proc Am Soc Clin Oncol 1995; 14: 138
   Google Scholar